Evaluation of Serum Preptin Levels in Patients With Polycystic Ovary Syndrome

NCT07736079 | Not Yet Recruiting

• 1 other identifier: KAEW2026.05.226
• Study Type: observational
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age and is strongly associated with insulin resistance and metabolic dysfunction. Preptin is a pancreatic peptide co-secreted with insulin and has been implicated in glucose metabolism and insulin resistance. However, limited data exist regarding serum preptin levels in patients with PCOS. The aim of this study is to evaluate serum preptin levels in women diagnosed with PCOS and to investigate the relationship between preptin levels and insulin resistance parameters.

Conditions

Polycystic Ovary Syndrome (PCOS); Insulin Resistance

Keywords

Polycystic Ovary Syndrome; Insulin Resistance; Preptin; Biomarker; Hyperandrogenism

Outcome Measures

Primary Outcomes (1)

• Serum Preptin Concentration

  Serum preptin concentration measured by enzyme-linked immunosorbent assay (ELISA) and expressed in pg/mL.

  Baseline

Secondary Outcomes (1)

• Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)

  Baseline

Study Arms (2)

PCOS Group

Patients diagnosed with PCOS according to the Rotterdam criteria.

Control Group

Women presenting with similar complaints but not meeting Rotterdam diagnostic criteria for PCOS.

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

This single-center prospective comparative cross-sectional study will include reproductive-aged women between 18 and 45 years of age who present to the Internal Medicine outpatient clinic with complaints of hirsutism, menstrual irregularity, and hyperandrogenism between June 15, 2026 and September 15, 2026. Participants diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria will constitute the PCOS group. The control group will consist of women with similar clinical complaints who do not meet the Rotterdam diagnostic criteria for PCOS. Only non-obese women with a body mass index (BMI) below 30 kg/m² will be included. Participants with pregnancy, breastfeeding, active infection, chronic systemic disease, rheumatologic or inflammatory disease, diabetes mellitus, hypertension, chronic renal failure, or those receiving treatment for PCOS within the last 6 months will be excluded. All participants will provide written informed consent before enrollment.

You may qualify if:

• Female participants aged 18-45 years
• Diagnosis of PCOS according to Rotterdam criteria
• BMI \<30 kg/m²
• No PCOS treatment during the previous 6 months
• Not pregnant or breastfeeding
• No active infection
• No rheumatologic or inflammatory disease
• No chronic systemic disease
• Written informed consent

You may not qualify if:

• Age \<18 years or \>45 years
• Pregnancy or breastfeeding
• PCOS treatment within the previous 6 months
• Active infection
• Rheumatologic or inflammatory disease
• Hypertension
• Diabetes mellitus
• Chronic kidney disease
• Refusal to participate

Sponsors & Collaborators

• GÜLDEN ANATACA: lead

MeSH Terms

Conditions

Polycystic Ovary Syndrome; Insulin Resistance; Hyperandrogenism

Condition Hierarchy (Ancestors)

Ovarian Cysts; Cysts; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Gonadal Disorders; Endocrine System Diseases; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; 46, XX Disorders of Sex Development; Disorders of Sex Development; Urogenital Abnormalities; Adrenogenital Syndrome; Male Urogenital Diseases; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Central Study Contacts

gülden ANATACA

CONTACT

+905059284244; ganataca@yahoo.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Target Duration: 12 Weeks
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Specialist Physician

Study Record Dates

• First Submitted: July 16, 2026
• First Posted: July 30, 2026
• Study Start: July 30, 2026
• Primary Completion (Estimated): September 30, 2026
• Study Completion (Estimated): September 30, 2026
• Last Updated: July 30, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share